Baher Krayem

Haifa, HA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Journal: EJHaem

Published: March 19, 2026

Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.

Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.

Journal: Blood advances

Published: March 10, 2026

Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.

Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.

Journal: Blood advances

Published: March 10, 2026

Intensive induction therapy with FLAG-idarubicinvenetoclax for fit older high-risk patients with acute myeloid leukemia.

Intensive induction therapy with FLAG-idarubicinvenetoclax for fit older high-risk patients with acute myeloid leukemia.

Journal: Haematologica

Published: December 25, 2025

FLAG-IDA-venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.

FLAG-IDA-venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.

Journal: Haematologica

Published: August 25, 2025

Novel therapies for acute myeloid leukemia. Does age still matter?

Novel therapies for acute myeloid leukemia. Does age still matter?

Journal: Blood reviews

Published: March 14, 2025

HiDAC Consolidation in AML: Comparable Outcomes With Reduced Toxicity Using a Three-Day Schedule (HiDAC-123).

HiDAC Consolidation in AML: Comparable Outcomes With Reduced Toxicity Using a Three-Day Schedule (HiDAC-123).

Journal: European journal of haematology

Published: March 11, 2025

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Journal: British journal of haematology

Published: September 30, 2024

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Journal: European journal of haematology

Published: August 29, 2024

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Journal: British journal of haematology

Published: March 27, 2024

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level.

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level.

Journal: Journal of clinical medicine

Published: August 04, 2023

Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review.

Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review.

Journal: Seminars in thrombosis and hemostasis

Published: December 19, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026